Enovis Corp - Understand $enov stock

$ENOV Market Cap: $2.717 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$2.002B

TTM

Gross Margin

57.02%

TTM

Net Earnings

-$119.2M

TTM

Current Assets

$1.203B

Q3 2024

Current Liabilities

$530.2M

Q3 2024

Current Ratio

226.9%

Q3 2024

Total Assets

$5.550B

Q3 2024

Total Liabilities

$2.217B

Q3 2024

Book Value

$3.333B

Q3 2024

Cash

$35.43M

Q3 2024

P/E

-22.79

Nov 29, 2024 EST

Free Cash Flow

-$61.88M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$1.707B	$1.563B	$3.854B	$3.071B	$3.327B	$3.667B	$3.300B	$3.186B	$3.434B	$4.624B	$4.207B	$3.914B	$693.4M
YoY Change	9.22%	-59.45%	25.52%	-7.71%	-9.25%	11.11%	3.59%	-7.24%	-25.74%	9.92%	7.5%	464.45%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$1.707B	$1.563B	$3.854B	$3.071B	$3.327B	$3.667B	$3.300B	$3.186B	$3.434B	$4.624B	$4.207B	$3.914B	$693.4M
Cost Of Revenue	$716.4M	$693.7M	$2.241B	$1.783B	$1.926B	$1.464B	$1.266B	$2.193B	$2.363B	$3.146B	$2.901B	$2.762B	$453.3M
Gross Profit	$990.8M	$869.4M	$1.614B	$1.288B	$1.401B	$729.4M	$671.6M	$992.4M	$1.072B	$1.479B	$1.306B	$1.152B	$240.1M
Gross Profit Margin	58.04%	55.62%	41.87%	41.95%	42.11%	19.89%	20.35%	31.15%	31.2%	31.98%	31.05%	29.44%	34.63%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$830.3M	$772.9M	$1.329B	$1.087B	$1.132B	$548.8M	$500.6M	$696.8M	$748.3M	$1.011B	$864.3M	$908.4M	$162.8M
YoY Change	7.43%	-41.86%	22.25%	-3.95%	106.31%	9.61%	-28.15%	-6.89%	-25.99%	16.99%	-4.86%	458.14%
% of Gross Profit	83.8%	88.9%	82.38%	84.42%	80.81%	75.24%	74.55%	70.21%	69.83%	68.38%	66.17%	78.85%	67.79%
Research & Development	$75.33M	$60.83M	$88.80M	$68.60M	$61.80M	$34.20M	$32.80M	$39.30M
YoY Change	23.84%	-31.5%	29.45%	11.0%	80.7%	4.27%	-16.54%
% of Gross Profit	7.6%	7.0%	5.5%	5.33%	4.41%	4.69%	4.88%	3.96%
Depreciation & Amortization	$217.1M	$203.0M	$262.9M	$246.2M	$215.6M	$81.21M	$72.69M	$128.8M	$137.0M	$174.7M	$119.3M	$183.4M	$22.60M
YoY Change	6.97%	-22.8%	6.78%	14.2%	165.5%	11.72%	-43.58%	-5.99%	-21.57%	46.51%	-34.97%	711.59%
% of Gross Profit	21.91%	23.35%	16.29%	19.12%	15.39%	11.13%	10.82%	12.98%	12.79%	11.81%	9.13%	15.92%	9.41%
Operating Expenses	$905.6M	$833.7M	$1.329B	$1.087B	$1.132B	$548.8M	$500.6M	$696.8M	$748.3M	$1.011B	$864.3M	$908.4M	$162.8M
YoY Change	8.62%	-37.28%	22.25%	-3.95%	106.31%	9.61%	-28.15%	-6.89%	-25.99%	16.99%	-4.86%	458.14%
Operating Profit	-$65.71M	-$71.18M	$256.6M	$162.3M	$203.6M	$151.5M	$135.6M	$236.8M	$265.6M	$409.6M	$406.4M	$140.0M	$25.91M
YoY Change	-7.68%	-127.73%	58.14%	-20.29%	34.37%	11.75%	-42.75%	-10.83%	-35.14%	0.78%	190.26%	440.45%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$19.75M	$24.05M	$72.59M	$104.3M	$119.5M	$49.08M	$40.11M	$30.28M	$47.50M	$51.31M	$103.6M	$91.57M	$5.919M
YoY Change	-17.89%	-66.87%	-30.37%	-12.75%	143.47%	22.38%	32.47%	-36.26%	-7.41%	-50.48%	13.13%	1447.05%
% of Operating Profit			28.29%	64.24%	58.69%	32.39%	29.58%	12.78%	17.88%	12.53%	25.49%	65.4%	22.85%
Other Income/Expense, Net	$25.66M	$2.088M	$0.00
YoY Change	1129.07%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$67.13M	-$2.069M	$165.4M	$58.03M	$50.49M	$92.36M	$48.56M	$206.5M	$218.1M	$358.2M	$302.8M	-$73.47M	-$27.65M
YoY Change	3144.47%	-101.25%	185.01%	14.92%	-45.33%	90.21%	-76.49%	-5.32%	-39.12%	18.31%	-512.15%	165.75%
Income Tax	-$13.29M	$36.12M	$66.70M	-$6.053M	$31.63M	-$29.51M	$2.483M	$51.77M	$41.17M	-$62.03M	$93.65M	$90.70M	$15.43M
% Of Pretax Income			40.33%	-10.43%	62.64%	-31.95%	5.11%	25.07%	18.87%	-17.31%	30.93%
Net Earnings	-$33.26M	-$13.29M	$71.66M	$42.63M	-$527.6M	$140.2M	$151.1M	$128.1M	$167.7M	$392.1M	$178.6M	-$64.40M	$4.555M
YoY Change	150.23%	-118.55%	68.11%	-108.08%	-476.36%	-7.21%	17.94%	-23.62%	-57.22%	119.51%	-377.36%	-1513.87%
Net Earnings / Revenue	-1.95%	-0.85%	1.86%	1.39%	-15.86%	3.82%	4.58%	4.02%	4.88%	8.48%	4.25%	-1.65%	0.66%
Basic Earnings Per Share	-$0.61	-$0.25	$0.47	$0.31	-$3.89	$1.17	$1.23	$1.04	$1.35	$3.06	$1.56	-$0.92	$0.10
Diluted Earnings Per Share	-$0.61	-$0.25	$0.46	$0.31	-$3.89	$1.16	$1.22	$1.04	$1.34	$3.02	$1.54	-$0.92	$0.10

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$36.19M	$24.30M	$680.3M	$97.07M	$109.6M	$77.15M	$411.6M	$208.8M
YoY Change	48.96%	-96.43%	600.8%	-11.46%	42.1%	-81.26%	97.13%
Cash & Equivalents	$36.19M	$24.30M	$680.3M	$97.07M	$109.6M	$77.15M	$262.0M	$208.8M
Short-Term Investments			$0.00				$149.6M
Other Short-Term Assets	$100.0M	$76.71M	$1.012B	$182.9M	$161.2M	$1.135B	$258.4M	$326.0M
YoY Change	30.39%	-92.42%	453.12%	13.49%	-85.8%	339.29%	-20.74%
Inventory	$468.8M	$426.6M	$356.2M	$564.8M	$571.6M	$359.7M	$429.6M	$365.0M
Prepaid Expenses
Receivables	$291.5M	$267.4M	$255.0M	$517.0M	$561.9M	$386.6M	$970.2M	$838.8M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$896.5M	$795.0M	$2.303B	$1.362B	$1.404B	$1.958B	$2.070B	$1.739B
YoY Change	12.77%	-65.48%	69.13%	-3.02%	-28.3%	-5.38%	19.05%
Property, Plant & Equipment	$334.3M	$303.6M	$311.6M	$660.9M	$664.6M	$327.2M	$552.8M	$537.7M
YoY Change	10.11%	-2.56%	-52.85%	-0.55%	103.13%	-40.82%	2.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$90.26M	$80.29M	$2.813B	$350.8M	$396.5M	$2.204B	$531.3M	$827.1M
YoY Change	12.41%	-97.15%	701.74%	-11.52%	-82.01%	314.86%	-35.76%
Total Long-Term Assets	$3.613B	$3.478B	$6.213B	$5.990B	$5.983B	$4.658B	$4.640B	$4.600B
YoY Change	3.87%	-44.01%	3.72%	0.12%	28.45%	0.38%	0.87%
Total Assets	$4.509B	$4.273B	$8.516B	$7.352B	$7.387B	$6.616B	$6.710B	$6.338B
YoY Change
Accounts Payable	$132.5M	$135.6M	$155.2M	$330.3M	$359.8M	$291.2M	$587.1M	$515.5M
YoY Change	-2.32%	-12.62%	-53.0%	-8.21%	23.54%	-50.4%	13.89%
Accrued Expenses	$219.8M	$193.1M	$197.9M	$360.3M	$398.6M	$218.5M	$304.7M	$275.9M
YoY Change	13.85%	-2.46%	-45.07%	-9.61%	82.47%	-28.3%	10.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$219.3M	$7.701M	$27.07M	$27.64M	$5.020M	$5.766M	$5.406M
YoY Change	-100.0%	2747.41%	-71.56%	-2.05%	450.64%	-12.94%	6.66%
Total Short-Term Liabilities	$369.6M	$565.2M	$1.024B	$811.7M	$857.3M	$1.199B	$1.097B	$1.060B
YoY Change	-34.61%	-44.78%	26.11%	-5.33%	-28.52%	9.29%	3.56%
Long-Term Debt	$466.2M	$40.00M	$2.079B	$2.204B	$2.284B	$1.192B	$1.055B	$1.287B
YoY Change	1065.41%	-98.08%	-5.7%	-3.5%	91.56%	12.99%	-17.99%
Other Long-Term Liabilities	$252.9M	$218.2M	$752.3M	$747.8M	$755.7M	$747.3M	$829.7M	$898.7M
YoY Change	15.86%	-70.99%	0.59%	-1.04%	1.13%	-9.94%	-7.67%
Total Long-Term Liabilities	$719.0M	$258.2M	$2.831B	$2.952B	$3.040B	$1.940B	$1.885B	$2.185B
YoY Change	178.42%	-90.88%	-4.1%	-2.89%	56.72%	2.9%	-13.74%
Total Liabilities	$1.091B	$825.2M	$3.899B	$3.808B	$3.945B	$3.346B	$3.209B	$3.442B
YoY Change	32.21%	-78.83%	2.37%	-3.48%	17.91%	4.27%	-6.75%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Basic Shares Outstanding	54.49M shares	54.07M shares	153.4M shares	136.8M shares	135.7M shares	120.3M shares	123.2M shares	122.9M shares	124.1M shares	121.1M shares	99.20M shares	91.07M shares	43.63M shares
Diluted Shares Outstanding	54.49M shares	54.07M shares	155.5M shares	138.9M shares	136.7M shares	120.8M shares	124.0M shares	123.2M shares	124.9M shares	122.7M shares	100.4M shares	91.07M shares	44.27M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.7167 Billion

About Enovis CORP

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 6,550 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. The company also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: ABBOTT LABORATORIES Axonics, Inc. CONMED Corp GLAUKOS Corp Integer Holdings Corp Inari Medical, Inc. INTEGRA LIFESCIENCES HOLDINGS CORP iRhythm Technologies, Inc. NUVASIVE INC TANDEM DIABETES CARE INC